CIK 0001281895
- Non-accelerated filer
- Smaller reporting company
ROCKET PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RCKT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 646-440-9100
- Business address
- 350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY, 10118
- Former names
- INOTEK PHARMACEUTICALS CORP
- 4 Open-market sale See Remarks sold 1,409 shares at $6.53 ($9,198)
- 4 Open-market sale See Remarks sold 1,582 shares at $6.53 ($10,327)
- 4 Open-market sale CEO sold 3,621 shares at $6.53 ($23,638)
- 4 Open-market sale General Counsel sold 946 shares at $6.53 ($6,175)
- 4 Open-market sale See Remarks sold 718 shares at $7.16 ($5,139)
- 4 Other acquisition Director acquired 14,220 shares (other)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy CEO bought 20,000 shares at $5.08 ($101,600)
- 4 Open-market buy See Remarks bought 21,099 shares at $4.70 ($99,165)
- 4 Open-market sale Chief Financial Officer sold 7,489 shares at $5.29 ($39,647)
- 4 Open-market sale See Remarks sold 15,093 shares at an average $14.84 ($223,965)
- 4 Open-market sale See Remarks sold 6,078 shares at $10.58 ($64,305)
- 4 Open-market sale General Counsel sold 3,222 shares at $10.58 ($34,089)
- 4 Open-market sale See Remarks sold 2,737 shares at $10.58 ($28,957)
- 4 Open-market sale CEO sold 16,303 shares at $10.58 ($172,486)
- 4 Grant or award General Counsel acquired 90,358 shares (grant or award)
- 4 Grant or award CEO acquired 81,655 shares (grant or award)
- 4 Grant or award See Remarks acquired 80,318 shares (grant or award)
- 4 Grant or award See Remarks acquired 57,786 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 90,358 shares (grant or award)
Page 5 of 21 · 406 filings